A Randomized, Double Blind, Parallel Group Study For Assessing The Efficacy And Safety Of Renvela Tablets For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease Not On Dialysis Versus Placebo
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Sevelamer (Primary)
- Indications Hyperphosphataemia
- Focus Registrational; Therapeutic Use
- Acronyms RECOVER
- Sponsors Sanofi
- 19 Aug 2019 Status changed from active, no longer recruiting to completed.
- 09 Jul 2019 Planned End Date changed from 1 Nov 2019 to 1 Aug 2019.
- 09 Jul 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Aug 2019.